← Back to Screener
Eikon Therapeutics, Inc. Common Stock (EIKN)
Price$8.96
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (4W)-10.03%
VGM Score16.82
Market Capitalization$542.61M
All Metrics
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-49.11%
10-Day Avg Trading Volume0.32M
EPS (Annual)$-6.01
ROI (Annual)-114.80%
Cash / Share (Quarterly)$6.22
ROA (Last FY)-54.52%
Cash Flow / Share (Annual)$-4.36
P/B Ratio1.92x
Net Income / Employee (Annual)$-844,400
EPS Incl Extra (Annual)$-6.01
Current Ratio (Annual)6.34x
Quick Ratio (Quarterly)6.12x
3-Month Avg Trading Volume0.41M
52-Week High$17.40
EPS Excl Extra (Annual)$-6.01
Quick Ratio (Annual)6.12x
13-Week Price Return-38.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.34x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.22
3-Month Return Std Dev98.95%
ROE (Last FY)-114.80%
EPS Basic Excl Extra (Annual)$-6.01
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return-40.27%
5-Day Price Return-16.96%
EPS Normalized (Annual)$-6.01
Month-to-Date Return-17.34%
EBITD / Share (Annual)$-5.93
Price vs S&P 500 (13W)-46.63%
Beta2.39x
52-Week Low$7.90
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-2.46est. -1.78
Analyst Recommendations
Apr 2026
May 2026
3.92
3.92
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EIKNEikon Therapeutics, Inc. Common Stock | — | — | F | $8.96 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing novel medicines to address serious unmet medical needs using its proprietary drug discovery platform. The company is advancing five product candidates (EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006) through clinical development.